Travere Therapeutics
Stock Forecast, Prediction & Price Target
Travere Therapeutics (TVTX) stock Price Target by analysts
$23.5
Potential upside: 36.62%
Travere Therapeutics price prediction
What is Travere Therapeutics stock analysts` prediction?
Travere Therapeutics stock forecast: Based on 8 Wall Street analysts` predicted price targets for Travere Therapeutics in the last 3 months, the avarage price target is $23.5, with a high forecast of $NaN. The average price target represents a 36.62% change from the last price of $17.2.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Travere Therapeutics stock Price Target by analysts
Full breakdown of analysts given Travere Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Liisa Bayko Evercore ISI | 0% 0/2 | 10 months ago | $33 91.86% upside | $17.5 | StreetInsider | Previous targets (1) |
Mohit Bansal Wells Fargo | 0% 0/1 | 11 months ago | $27 56.97% upside | $17.87 | StreetInsider | Previous targets (0) |
Liisa Bayko Evercore ISI | 0% 0/2 | 11 months ago | $30 74.41% upside | $18.07 | TheFly | Previous targets (1) |
Jason Zemansky Bank of America Securities | 0% 0/1 | 11 months ago | $20 16.27% upside | $15.21 | TheFly | Previous targets (0) |
Carter Gould Barclays | 0% 0/1 | 11 months ago | $18 4.65% upside | $13.99 | TheFly | Previous targets (0) |
Vamil Divan Guggenheim | 0% 0/2 | 12 months ago | $23 33.72% upside | $15.04 | TheFly | Previous targets (1) |
Greg Harrison Bank of America Securities | 0% 0/1 | 12 months ago | $18 4.65% upside | $14.01 | StreetInsider | Previous targets (0) |
Ed Arce H.C. Wainwright | 0% 0/3 | 12 months ago | $18 4.65% upside | $15.04 | TheFly | Previous targets (2) |
Ed Nash Canaccord Genuity | 0% 0/2 | 12 months ago | $23 33.72% upside | $12.7 | StreetInsider | Previous targets (1) |
Vamil Divan Guggenheim | 0% 0/2 | 12 months ago | $25 45.34% upside | $12.62 | StreetInsider | Previous targets (1) |
Nicole Gabreski Piper Sandler | 0% 0/1 | about 1 year ago | $12 -30.23% downside | $8.96 | StreetInsider | Previous targets (0) |
Ed Arce H.C. Wainwright | 0% 0/3 | about 1 year ago | $20 16.27% upside | $9.24 | TheFly | Previous targets (2) |
Ed Nash Canaccord Genuity | 0% 0/2 | over 1 year ago | $18 4.65% upside | $6.55 | StreetInsider | Previous targets (1) |
Ed Arce H.C. Wainwright | 0% 0/3 | over 1 year ago | $19 10.46% upside | $5.48 | TheFly | Previous targets (2) |
Unknown Wells Fargo | N/A | almost 3 years ago | $28 62.79% upside | $20.08 | Benzinga | N/A |
Travere Therapeutics Financial Estimates
Travere Therapeutics Revenue Estimates
Travere Therapeutics EBITDA Estimates
Travere Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $227.49M N/A | $212.01M -6.80% | $145.23M -31.49% | Avg: $324.97M Low: $261.88M High: $511.92M avg. 123.75% | Avg: $449.98M Low: $374.05M High: $632.10M avg. 38.46% | Avg: $434.72M Low: $361.37M High: $610.67M avg. -3.39% | Avg: $547.09M Low: $454.77M High: $768.52M avg. 25.84% |
Net Income
% change YoY
| $-180.09M N/A | $-278.48M -54.63% | $-111.39M 59.99% | Avg: $-145.44M Low: $-175.27M High: $18.56M avg. -30.56% | Avg: $-6.69M Low: $-89.12M High: $146.30M avg. 95.39% | Avg: $33.91M Low: $26.47M High: $51.76M avg. 606.23% | Avg: $94.81M Low: $74.01M High: $144.70M avg. 179.56% |
EBITDA
% change YoY
| $-137.28M N/A | $-244.31M -77.96% | $-326.24M -33.53% | Avg: $-217.63M Low: $-342.82M High: $-175.38M avg. 33.29% | Avg: $-301.34M Low: $-423.31M High: $-250.49M avg. -38.46% | Avg: $-291.13M Low: $-408.96M High: $-242.00M avg. 3.39% | Avg: $-366.38M Low: $-514.66M High: $-304.55M avg. -25.84% |
EPS
% change YoY
| -$3.01 N/A | -$4.37 -45.18% | -$1.5 65.67% | Avg: -$1.62 Low: -$2.36 High: $0.25 avg. -8.32% | Avg: $0.08 Low: -$1.2 High: $1.97 avg. 105.02% | Avg: $0.46 Low: $0.36 High: $0.7 avg. 459.16% | Avg: $1.28 Low: $1 High: $1.95 avg. 179.56% |
Operating Expenses
% change YoY
| $360.21M N/A | $455.98M 26.58% | $521.92M 14.46% | Avg: $304.60M Low: $245.47M High: $479.83M avg. -41.63% | Avg: $421.77M Low: $350.60M High: $592.48M avg. 38.46% | Avg: $407.47M Low: $338.72M High: $572.39M avg. -3.39% | Avg: $512.80M Low: $426.27M High: $720.35M avg. 25.84% |
FAQ
What is Travere Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 212.65% in 2025-2028.
We have gathered data from 10 analysts. Their low estimate is -175.27M, average is -145.44M and high is 18.56M.
What is Travere Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 46.16% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $261.88M, average is $324.97M and high is $511.92M.
What is Travere Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 183.85% in 2025-2028.
We have gathered data from 10 analysts. Their low earnings per share estimate is -$2.36, average is -$1.62 and high is $0.25.
What is the best performing analyst?
In the last twelve months 8 analysts have been covering Travere Therapeutics stock. The most successful analyst is Liisa Bayko.